Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS

被引:0
作者
Roberta Ciarapica
Elena Carcarino
Laura Adesso
Maria De Salvo
Giorgia Bracaglia
Pier Paolo Leoncini
Alessandra Dall’Agnese
Federica Verginelli
Giuseppe M Milano
Renata Boldrini
Alessandro Inserra
Stefano Stifani
Isabella Screpanti
Victor E Marquez
Sergio Valente
Antonello Mai
Pier Lorenzo Puri
Franco Locatelli
Daniela Palacios
Rossella Rota
机构
[1] IRCCS,Department of Oncohematology, Laboratory of Angiogenesis, Ospedale Pediatrico Bambino Gesù
[2] IRCCS Fondazione Santa Lucia,Departments of Pathology, Ospedale Pediatrico Bambino Gesù
[3] IRCCS,Departments of Surgery, Ospedale Pediatrico Bambino Gesù
[4] IRCCS,Centre for Neuronal Survival, Montreal Neurological Institute
[5] McGill University,Department of Molecular Medicine
[6] Sapienza University,Chemical Biology Laboratory, Frederick National Laboratory for Cancer Research, CCR
[7] National Cancer Institute,Istituto Pasteur, Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco
[8] NIH,Muscle Development and Regeneration Program
[9] Sapienza University,Dipartimento di Scienze Pediatriche
[10] Sanford-Burnham Medical Research Institute,undefined
[11] Università di Pavia,undefined
来源
BMC Cancer | / 14卷
关键词
EZH2; Histone methyltransferase; rhabdomyosarcoma; Polycomb proteins; Differentiation; DZnep; EZH2 catalytic inhibitors;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 468 条
[1]  
Loeb DM(2008)Pediatric soft tissue sarcomas Surg Clin North Am 88 615-627
[2]  
Thornton K(2010)Selecting multimodal therapy for rhabdomyosarcoma Expert Rev Anticancer Ther 10 1285-1301
[3]  
Shokek O(2010)Outcomes for children and adolescents with cancer: challenges for the twenty-first century J Clin Oncol 28 2625-2634
[4]  
Sultan I(1999)Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group J Clin Oncol 17 3487-3493
[5]  
Ferrari A(2005)Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma Cancer 104 183-190
[6]  
Smith MA(2008)Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups J Clin Oncol 26 2384-2389
[7]  
Seibel NL(1993)Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis Science 259 1450-1453
[8]  
Altekruse SF(2008)NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma Cancer Cell 14 369-381
[9]  
Ries LA(2009)The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation J Clin Invest 119 2366-2378
[10]  
Melbert DL(2012)Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo Cell Death Differ 19 871-881